文献速递其他结缔组织病类风湿关节炎

系统性自身免疫风湿病相关进展性肺纤维化的结局:ILD-PRO登记研究真实世界数据

Outcomes in Progressive Pulmonary Fibrosis in Systemic Autoimmune Rheumatic Diseases: Real-World Data From the ILD-PRO Registry.
PubMed 文献 · Arthritis Rheumatol · 2026-08-04

基于美国多中心前瞻性ILD-PRO登记研究,纳入585例系统性自身免疫风湿病相关进展性肺纤维化(SARD-PPF)患者,评估基线特征、治疗模式与结局。入组时生理损害明显,24个月内各亚型ILD进展比例为31.3%–62.1%,死亡或肺移植比例为9.3%–37.6%。校正年龄、性别和/或基线FVC%预计值后,各SARD亚型间结局无显著差异。

要点

  • SARD-PPF患者入组时肺功能损害明显,治疗负担高。
  • 24个月内各亚型ILD进展与死亡/肺移植风险均较高。
  • 校正人口学与基线严重度后,各SARD亚型结局总体相似。

核心结论

  • SARD-PPF以显著生理损害、高治疗负担及高进展和死亡/肺移植风险为特征。
  • 校正年龄、性别和/或基线FVC%预计值后,各SARD诊断间结局总体相似,支持以表型为核心的风险分层。

研究设计与样本

  • ILD-PRO登记为美国前瞻性多中心登记研究,纳入符合进展性肺纤维化(PPF)标准的非特发性肺纤维化ILD患者。
  • 共分析585例SARD-PPF患者,描述基线特征并评估SARD亚型与临床结局的关联。

主要发现

  • 入组时中位FVC为64.5%预计值,中位DLCO为38.0%预计值。
  • 39.2%使用补充氧,73.9%接受免疫调节治疗,22.6%使用尼达尼布。
  • 24个月内各SARD亚型ILD进展比例为31.3%–62.1%,死亡或肺移植比例为9.3%–37.6%。
  • 类风湿关节炎相关PPF的未校正ILD进展概率最高,但校正后无显著亚型差异。

临床怎么用

  • 对SARD-ILD患者应系统监测肺功能与病情进展,并及时优化管理。
  • 风险分层可关注基线生理损害与表型特征,而非仅依据SARD诊断分类。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease-associated progressive pulmonary fibrosis (SARD-PPF) and evaluated whether outcomes differed by SARD subtype. METHODS: The ILD-PRO Registry is a prospective multicenter US registry of patients with PPF. Eligible participants had an interstitial lung disease (ILD) other than idiopathic pulmonary fibrosis with reticulation and traction bronchiectasis on high-resolution computed tomography and/or lung biopsy and met the criteria for PPF within the prior 24 months. Among patients with SARD-PPF, we described baseline characteristics and evaluated associations between SARD subtype and clinical outcomes. RESULTS: Among 585 patients with SARD-PPF, physiologic impairment at enrollment was substantial (median forced vital capacity [FVC] 64.5% predicted; median diffusing capacity of the lungs for carbon monoxide 38.0% predicted): 39.2% used supplemental oxygen, 73.9% were receiving immunomodulatory therapy, and 22.6% were taking nintedanib. By 24 months, 31.3% to 62.1% of patients experienced ILD progression across SARD subtypes, and 9.3% to 37.6% experienced death or lung transplant. Rheumatoid arthritis-PPF showed the highest unadjusted probability of ILD progression; however, no significant subtype-associated differences were observed in analyses adjusted for age, sex, and/or baseline FVC % predicted. CONCLUSION: In a large prospective multicenter US cohort, SARD-PPF was characterized by advanced physiologic impairment, high treatment burden, and high risk for further progression and death or lung transplant. After accounting for demographic factors and baseline severity, outcomes were broadly similar across SARD diagnoses, supporting phenotype-focused risk stratification and underscoring the need for systematic monitoring and timely optimization of management for SARD-ILD.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Bracken SJ, Weber JM, Neely ML, et al. Outcomes in Progressive Pulmonary Fibrosis in Systemic Autoimmune Rheumatic Diseases: Real-World Data From the ILD-PRO Registry. Arthritis Rheumatol. 2026. PMID: 42549477. doi:10.1002/art.70283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。